Enlicitide decanoate (Merck's MK-0616) is the highest-profile oral cyclic peptide drug program in late-stage development outside the GLP-1 class. The molecule is a macrocyclic peptide designed to inhibit PCSK9, the protease that down-regulates the LDL receptor and which has become a validated target for hyperlipidemia following the success of monoclonal antibody PCSK9 inhibitors (evolocumab, alirocumab). Where the existing approved drugs require injection, enlicitide is dosed orally as a pill, a development that has potential to widen the PCSK9-inhibition addressable market by orders of magnitude.
The FDA approved enlicitide as LIPFENDRA (20 mg tablets) on July 16, 2026 as the first once-daily oral PCSK9 inhibitor to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The Phase 3 CORALreef program supported approval with 56% placebo-adjusted LDL-C reduction in CORALreef Lipids and 59% in CORALreef HeFH — matching injectable PCSK9 monoclonal antibodies (Amgen Repatha, Regeneron/Sanofi Praluent). Merck priced LIPFENDRA at $315 per month, roughly one-third the injectable-class list prices. The approval validates the macrocyclic peptide modality as a commercial oral competitor to small-molecule and monoclonal-antibody drug classes.
The broader context: the June 2026 C&EN feature drawing on CAS Content Collection data documented the cyclic peptide patenting surge from 2020 through April 2026, with Bicycle Therapeutics and Bristol Myers Squibb among the most active corporate filers. Cyclic and macrocyclic peptides are projected to grow from $1.22B in 2024 to $4.76B by 2030 at 21.44% CAGR, with enlicitide cited as the oral-pill proof point. Stories tagged here track the FDA review timeline, CORALreef program data, and how the molecule's commercial trajectory affects the macrocyclic peptide modality more broadly. See [[merck]], [[cyclic-peptide]], [[macrocyclic-peptide]], and [[pcsk9]] for adjacent threads.
Merck (NYSE: MRK) reported Q2 2026 earnings Tuesday August 4, 2026 before market open with quarterly revenue of $16.61 billion (+5% year-over-year), beating analyst consensus of $16.36 billion. Keytruda (pembrolizumab) generated $8.37 billion in Q2 sales (+5% YoY), exceeding analyst expectations of $8.27 billion; the total includes $463 million from the newly-launched more convenient injectable Keytruda formulation. Merck highlighted the July 16, 2026 LIPFENDRA (enlicitide) FDA approval as the first once-daily oral macrocyclic peptide PCSK9 inhibitor in the class, priced at $315 per month with peak sales potential of $5 billion by 2034. Full-year 2026 revenue guidance was raised to $66.3-67.3 billion from the prior $65.8-67 billion range, but adjusted EPS guidance was cut to $2.66-2.76 to reflect a one-time $5.7 billion ($2.31 per share) charge tied to the Terns Pharmaceuticals acquisition that closed in H1 2026. Merck shares rose 0.6% in early trading to $128.54. Broader pipeline highlights include continued growth of Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma), and Capvaxive (pneumococcal vaccine), plus the integration of Terns and Cidara acquisitions. Merck has beaten consensus in each of the trailing four quarters.
Merck (NYSE: MRK) Q2 2026 earnings pre-day positioning ahead of the Tuesday August 4, 2026 before-market-open report. Zacks analyst consensus: $16.33 billion revenue, $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025). Analyst focus areas: Keytruda (pembrolizumab) sales trajectory (Zacks estimate $8.06 billion Q2, driven by earlier-stage indication uptake and continued metastatic-setting momentum) ahead of the 2028 US patent cliff that ends Keytruda exclusivity; the initial commercial ramp of LIPFENDRA (enlicitide) oral macrocyclic peptide PCSK9 inhibitor following the July 16, 2026 FDA approval, with peak sales potential estimated at $5 billion by 2034 and analyst commentary describing the safety label as 'the cleanest in the class'; contribution from Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma), and Capvaxive (pneumococcal vaccine); and the integration of the Terns Pharmaceuticals and Cidara Therapeutics acquisitions closed in H1 2026. Merck has beaten earnings expectations in each of the trailing four quarters with a 7.75% average earnings surprise; analyst attention also on potential FY 2026 revenue guidance revision from the prior $65.8-67 billion range and non-GAAP EPS guidance from $5.04-5.16.
Merck (NYSE: MRK) reports Q2 2026 earnings Tuesday August 4, 2026 before market open with Zacks analyst consensus at $16.33 billion revenue and $1.36 diluted EPS (-36.2% year-over-year from $2.13 in Q2 2025). Analyst focus areas: Keytruda (pembrolizumab) sales trajectory with the Zacks estimate at $8.06 billion Q2, driven by earlier-stage indication uptake and continued metastatic-setting momentum ahead of the 2028 US patent cliff; the initial commercial launch of LIPFENDRA (enlicitide) macrocyclic peptide oral PCSK9 inhibitor following the July 16, 2026 FDA approval at $315/month list price ($10.50 per tablet), with peak sales potential estimated at $5 billion by 2034; the emerging contribution of Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma and VHL disease), and Capvaxive (pneumococcal vaccine); and pipeline signal from the Terns Pharmaceuticals and Cidara Therapeutics acquisitions completed in H1 2026. Merck has beaten earnings expectations in each of the trailing four quarters with a 7.75% average earnings surprise. Beyond Q2 specifically, analyst attention will focus on the FY 2026 revenue guidance ($65.8-67 billion range on the prior call) and non-GAAP EPS guidance ($5.04-5.16 range) for revisions.
Merck LIPFENDRA (enlicitide) commercial-launch details firmed up in the days following Thursday July 16, 2026 FDA approval. List price: $10.50 per tablet, or $315 per 30-day supply before insurance discounts, manufacturer support, or pharmacy benefit adjustments. Distribution channel: standard retail and mail-order pharmacies under the pharmacy benefit, which contrasts with Novartis Leqvio (inclisiran) that runs through the medical benefit due to healthcare-provider subcutaneous administration. Expected pharmacy availability: within weeks of approval. The pharmacy benefit pathway matters for real-world access because it eliminates the buy-and-bill logistics that have slowed injectable PCSK9 adoption (Repatha, Praluent, Leqvio) and puts LIPFENDRA on the same pharmacy shelf as statins and cheaper oral non-statin drugs like Nexletol (bempedoic acid) and Zetia (ezetimibe). The macrocyclic peptide's ability to survive gastrointestinal enzymes is what allows the oral delivery model that unlocks the pharmacy-benefit distribution advantage.
Analyst coverage of Merck's LIPFENDRA (enlicitide) FDA approval (Thursday July 16) crystallized Friday. Financial analysts projected LIPFENDRA can generate more than $2 billion in annual sales after a few years on the market. RBC Capital Markets described the label as 'the cleanest in the PCSK9 class,' noting zero contraindications or hypersensitivity warnings, unlike the currently approved injectable PCSK9 competitors (Amgen Repatha/evolocumab, Regeneron/Sanofi Praluent/alirocumab, and Novartis Leqvio/inclisiran). In supporting Phase 3 data, LIPFENDRA statistically outperformed other oral non-statin drugs (Nexletol/bempedoic acid and Zetia/ezetimibe) in adjunctive hypercholesterolemia populations. LIPFENDRA continues to be evaluated in the large cardiovascular outcomes trial CORALreef Outcomes (NCT06008756), which Merck confirmed has completed enrollment with more than 14,500 participants. It is not yet known whether LIPFENDRA reduces cardiovascular morbidity and mortality; the outcomes trial will address that question. Additional data on the safety profile: in CORALreef Lipids, adverse-reaction frequencies were similar between LIPFENDRA and placebo; in CORALreef HeFH the most common adverse reactions more frequent versus placebo were diarrhea (7% vs. 2%) and dizziness (9% vs. 4%), with discontinuation rates similar to placebo.
The US Food and Drug Administration approved Merck's LIPFENDRA (enlicitide) 20 mg tablets Thursday July 16, 2026 as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). LIPFENDRA is a novel macrocyclic peptide and becomes the first FDA-approved oral PCSK9 inhibitor. In the registrational Phase 3 CORALreef Lipids trial, enlicitide achieved a 56% placebo-adjusted LDL-C reduction; in CORALreef HeFH the reduction was 59%. Every other FDA-approved PCSK9 inhibitor (Amgen's Repatha/evolocumab, Regeneron/Sanofi's Praluent/alirocumab) is delivered by subcutaneous injection every two to four weeks; enlicitide is the first approved as a once-daily oral tablet. Merck priced LIPFENDRA at $315 per month list price, roughly one-third the approximately $700-900/month list prices of the injectable PCSK9 antibodies. The approval extends the macrocyclic peptide platform's clinical validation and opens a new oral chapter for a drug class that had been injectable-only since the first FDA approvals in 2015.
A Chemical & Engineering News feature published in June 2026, drawing on data from the CAS Content Collection, documented the cyclic-peptide patenting surge over 2020 to April 2026. Chinese universities are the top filers globally on cyclic peptides. Outside China, US universities lead. Among corporates, Bicycle Therapeutics and Bristol Myers Squibb were called out for sustained patent activity covering cancer, infectious, inflammatory, and autoimmune disease indications. The article frames cyclic peptides as bridging the small-molecule and biologic divide: enhanced conformational rigidity, elimination of unstable terminal residues, and improved metabolic stability are the structural advantages that allow some cyclic peptides to be dosed orally. Merck's enlicitide decanoate (MK-0616, oral PCSK9 macrocyclic peptide for hyperlipidemia) was cited as the proof point for oral-pill cyclic-peptide drug development; an enlicitide NDA submission was underway as of mid-2026. The broader market backdrop: macrocyclic and stapled peptides are projected to grow from $1.22 billion in 2024 to $4.76 billion by 2030 at a 21.44% CAGR, driven mostly by oncology pipelines and the macrocyclic deal flow that includes the Unnatural Products-Novartis $1.7-1.8B cardiovascular pact (February 2026), Biogen-Dayra $50M+ immunology pact (November 2025), and the Parabilis Helicon platform (Regeneron $2.3B collaboration, June 10 $670M record IPO).
Joelle Pelletier's perspective in Science (volume 392, pages 582-583, published online May 8) accompanies the Merck enlicitide biocatalytic synthesis paper and frames the enzyme-cascade route — engineered enzymes plus chromatography-free crystallization to cut step count by more than half — as a template that goes well beyond enlicitide. The piece argues that the limiting step for oral macrocyclic peptide therapeutics has been the manufacturing cost of multi-step protected-residue chemistry, not pharmacology or pharmacokinetics; biocatalysis collapses the cost curve and unlocks a pipeline of oral peptides at large molecular weights that have been quietly stuck in preclinical or Phase 1 economics. The framing matters as enlicitide (oral PCSK9 inhibitor with 57% LDL-C reduction at 24 weeks) heads toward NDA filing.
Merck scientists published in Science a convergent biocatalytic synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor and macrocyclic peptide. A tailored suite of engineered enzymes catalyzes selective peptide fragment formation, coupling, and macrocyclization in a protecting-group-free sequence; combined with chromatography-free crystallizations, the route reduces step count by more than half versus prior state-of-the-art methods. Enlicitide is in Phase 3 (CORALreef, with –55.8% LDL-C reported earlier in 2026) and would be the first oral PCSK9 inhibitor if approved. The paper matters beyond enlicitide: protein-engineering-led cascades shift the cost basis for any large macrocyclic peptide program facing peptide-CDMO bottlenecks.